Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Martín-Richard, M. Muñoz, J. Albanell, L. Colomo, M. Bellet, M. Rey, J. Tabernero, C. Alonso, A. Cardesa, P. Gascón, P. Fernández (2004)
Serial Topoisomerase II Expression in Primary Breast Cancer and Response to Neoadjuvant Anthracycline-Based ChemotherapyOncology, 66
F. Cardoso, V. Durbecq, D. Larsimont, M. Paesmans, J. Leroy, G. Rouas, C. Sotiriou, N. Renard, V. Richard, M. Piccart, A. Leo (2004)
Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer.International journal of oncology, 24 1
M. Colozza, A. Sidoni, A. Mosconi, A. Cavaliere, G. Bisagni, S. Gori, V. Angelis, A. Frassoldati, R. Cherubini, A. Bian, C. Rodinò, B. Mazzocchi, Zhasmina Mihailova, E. Bucciarelli, M. Tonato (2005)
HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results.Clinical breast cancer, 6 3
J. Champoux (2001)
DNA topoisomerases: structure, function, and mechanism.Annual review of biochemistry, 70
Michael Orr, Patrick O'Connor, Kurt Kohn (2000)
Effects of c-erbB2 overexpression on the drug sensitivities of normal human mammary epithelial cells.Journal of the National Cancer Institute, 92 12
A. Vincent-Salomon, M. Jouve, P. Génin, P. Fréneaux, B. Sigal‐Zafrani, M. Caly, P. Beuzeboc, P. Pouillart, X. Sastre-Garau (2002)
HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic processCancer, 94
H. Turley, M. Comley, S. Houlbrook, N. Nozaki, A. Kikuchi, Ian Hickson, K. Gatter, A. Harris (1997)
The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues.British Journal of Cancer, 75
(1996)
Expression of topoisomerase 2alpha is associated with rapid cell proliferation
(2000)
Amplification and deletion of topoisomerase 2 a gene are common in ErbB 2 amplified breast cancer and alter sensitivuty to doxorubicin
D. Slamon, G. Clark, S. Wong, W. Levin, A. Ullrich, W. McGuire (1987)
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science, 235 4785
(2009)
DNA Topoisomerases
P. Rudolph, H. Olsson, G. Bonatz, Virgo Ratjen, Hendrik Bolte, B. Baldetorp, M. Fernö, R. Parwaresch, P. Alm (1999)
Correlation between p53, c‐erbB‐2, and topoisomerase IIα expression, DNA ploidy, hormonal receptor status and proliferation in 356 node‐negative breast carcinomas: prognostic implicationsThe Journal of Pathology, 187
E. Manna, L. Teixeira, M. Alvarenga (2006)
Association between Immunohistochemical Expression of Topoisomerase IIα, Her2 and Hormone Receptors and Response to Primary Chemotherapy in Breast CancerTumori Journal, 92
A. Leo, J. Isola (2003)
Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning?Clinical breast cancer, 4 3
(1992)
Prognostic importance of c-erb B2 expression in breast cancer
(1987)
pression of topoisomerase 2 alpha is associated with rapid cell proliferation , aneuploidy and cerbB 2 expression in breast cancer
P. Fritz, C. Cabrera, Jürgen Dippon, A. Gerteis, W. Simon, W. Aulitzky, Heiko Kuip (2005)
c-erbB2 and topoisomerase IIα protein expression independently predict poor survival in primary human breast cancer: a retrospective studyBreast Cancer Research, 7
P. Kauraniemi, M. Bärlund, O. Monni, A. Kallioniemi (2001)
New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays.Cancer research, 61 22
(1996)
Expression of topoisomerase 2alpha is associated with rapid cell proliferation, aneuploidy and c-erbB2 expression in breast cancer
T. Järvinen, M. Tanner, M. Bärlund, Å. Borg, J. Isola (1999)
Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer.Genes, chromosomes & cancer, 26 2
D. Miles, W. Harris, C. Gillett, Philip Smith, D. Barnes (1999)
Effect of c‐erbB2 and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracilInternational Journal of Cancer, 84
(2001)
Prognostic importance of cerb B 2 expression in
V. Durbecq, C. Desmed, M. Paesmans, F. Cardoso, A. Leo, M. Mano, G. Rouas, J. Leroy, C. Sotiriou, M. Piccart, D. Larsimont (2004)
Correlation between topoisomerase-IIalpha gene amplification and protein expression in HER-2 amplified breast cancer.International journal of oncology, 25 5
S. Paik, J. Bryant, E. Tan-chiu, G. Yothers, C. Park, D. Wickerham, N. Wolmark (2000)
HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15.Journal of the National Cancer Institute, 92 24
(2004)
Facts and controversies in systemic treatment of breast cancer
S. Ménard, P. Valagussa, S. Pilotti, L. Gianni, E. Biganzoli, P. Boracchi, G. Tomasic, P. Casalini, E. Marubini, M. Colnaghi, N. Cascinelli, G. Bonadonna (2001)
Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 2
T. Järvinen, M. Tanner, M. Bärlund, Å. Borg, J. Isola (1999)
Characterization of topoisomerase IIα gene amplification and deletion in breast cancerGenes, 26
(2000)
Topoisomerase 2 alpha expression in breast cancer: correaltion with clinical variables
(1993)
Prognostic factrors and response to therapy in breast cancer
L. Harris, L. Yang, V. Liotcheva, S. Pauli, J. Iglehart, O. Colvin, T. Hsieh (2001)
Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research, 7 6
(1996)
Annu Rev Biochem
The aim of this study was to determine the relationship between amplification of HER2 (Human epidermal growth factor receptor 2) and Topo2a (topoisomerase 2a) and their influence on prognosis in metastatic breast cancer (MBC) patients. Amplification of both HER2 and Topo2a genes was determined by chromogenic in situ hybridization (CISH) in primary tumor tissue of 71 MBC patients. Starting point for follow-up was the time of diagnosis of metastatic disease. Although there was significant correlation between HER2 amplification and Topo2a alterations, Topo2a amplification was not strictly related to HER2 amplification. Follow-up of patients showed that there was no difference in MBC survival between HER2-nonamplified and HER2-amplified patients for subgroup as whole, but there was significant difference in MBC survival between patients with and without Topo2a amplification. HER2 amplification showed prognostic value in subgroups of patients, as well as Topo2a. Combination of these two genes with different status (nonamplified, amplified, coamplified) indicated that they might have additive effect. Also, it has been shown that Topo2a-amplified cases have poorer survival than Topo2a-nonamplified, when treated with CMF therapy. Topo2a amplification seems to be more promising biomarker of MBC survival, than HER2, and potential marker of resistance to CMF therapy.
Disease Markers – IOS Press
Published: Jan 1, 2009
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.